A recent phase II double-blind randomized controlled trial showed that anifrolumab can effectively reduce CRP levels in patients with grade III/IV lupus nephritis, but the primary endpoint of the trial (24-hour urine protein to creatinine ratio) was not met (25). This evidence concerns the gene CRP and lupus nephritis.